How effective is CIMAvax-EGF?
The 12 and 24 months survival rate was of 44.1 and 23.3%, respectively. In summary, CIMAvax-EGF was safe in patients with NSCLC at advanced stages treated in primary care facilities.
Is CIMAvax approved by the FDA?
Today, CIMAVax was approved by the Food and Drug Administration (FDA) for clinical trials at Roswell Park and the first trial is scheduled to begin in 30 days.
Is CIMAvax an immunotherapy?
CIMAvax-EGF is a lung cancer treatment that was developed in Cuba. It is a type of immunotherapy that harnesses the body’s immune system to fight lung cancer.
How is CIMAvax administered?
SAGE recommends the use of Sinovac-CoronaVac vaccine as 2 doses (0.5 ml) given intramuscularly. SAGE recommends that a third, additional dose of the Sinovac vaccine be offered to persons aged 60 and above as part of an extension of the primary series.
Does CIMAvax work on other cancers?
It has been suggested that CimaVax may also be effective in other types of cancer that are dependent on EGF/EGFR, including many cases of prostate cancer.
Where is CIMAvax available?
Cimavax is currently available in Cuba, Colombia, Peru, Bosnia-Herzegovina and Paraguay. Vaxira, which one Cuban clinical trial indicates can extend life by up to two months, is currently undergoing more testing in Argentina. It is available in that country and in Cuba.
What is the efficacy of Vero cell vaccine?
The results showed that the participants vaccinated with medium dose (600SU) and high dose (1200SU) vaccines for 28 days, and then the positive seroconversion rate reached to over 94.1%.
How effective will the Pfizer vaccine be?
How well it works: When Pfizer-BioNTech applied for FDA authorization for its vaccine in December 2020, its initial Phase 3 clinical data surpassed expectations with 95% efficacy, based on an independent analysis by the FDA.
Where is Vaxira available?
Is CIMAvax a vaccine?
CimaVax-EGF is a vaccine used to treat cancer, specifically non-small-cell lung carcinoma (NSCLC). CIMAvax-EGF is composed of recombinant human epidermal growth factor (EGF) conjugated to a protein carrier. The vaccine was developed by the Center of Molecular Immunology, Havana, Cuba.
Who makes CIMAvax?
A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence
| Responsible Party: | Roswell Park Cancer Institute |
| ClinicalTrials.gov Identifier: | NCT04298606 History of Changes |
What type of vaccine is Vero cell?
Sinopharm [Vero Cell]- Inactivated, COVID-19 vaccine The Sinopharm COVID-19 vaccine (vero cell), inactivated vaccine resource includes key information on the vaccine specific requirements.